ERICA KING: Open Payments
NPI 1891376174 · BIRMINGHAM, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,714 in 86 payments from 34 companies in 2025. Trend: 2023 $47 · 2024 $3,029 · 2025 $2,714
Food & beverage: $1,518Long term medical supply or device loan: $1,097Education: $99
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 18 | $1,239 |
| Daiichi Sankyo Inc. | 2 | $118 |
| Janssen Biotech, Inc. | 5 | $116 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $96 |
| Celgene Corporation | 4 | $75 |
| Alnylam Pharmaceuticals Inc. | 3 | $70 |
| Pharmacosmos Therapeutics Inc. | 3 | $69 |
| Alexion Pharmaceuticals, Inc. | 3 | $62 |
| CSL Behring | 2 | $60 |
| Stemline Therapeutics Inc. | 3 | $60 |
Products named: KISQALI, Enhertu, REBLOZYL, FRUZAQLA, GIVLAARI, MONOFERRIC, ULTOMIRIS, Hizentra.
Industry payments across AL — which companies pay providers there.
